OTCMKTS:BRTX

BioRestorative Therapies - BRTX Stock Forecast, Price & News

$3.02

+0.09 (+3.07%)

(As of 12/8/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.93
▼
$3.35
50-Day Range: $2.58
▼
$3.68
52-Week Range: $2.46
▼
$6.25

Volume: 18,805 shs
Average Volume: 42,413 shs
Market Capitalization: $11.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About BioRestorative Therapies (OTCMKTS:BRTX) Stock

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BRTX Stock News Headlines

December 7, 2022 | americanbankingnews.com

BioRestorative Therapies (OTCMKTS:BRTX) Now Covered by Roth Capital

December 6, 2022 | finance.yahoo.com

EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome

December 6, 2022 | finance.yahoo.com

BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

December 5, 2022 | finance.yahoo.com

BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

November 29, 2022 | finance.yahoo.com

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022

November 16, 2022 | finance.yahoo.com

BioRestorative Therapies Third Quarter 2022 Earnings: US$1.28 loss per share (vs US$4.99 loss in 3Q 2021)

November 16, 2022 | finance.yahoo.com

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

October 31, 2022 | finance.yahoo.com

See What’s Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!

October 31, 2022 | finance.yahoo.com

See What’s Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!

October 28, 2022 | benzinga.com

See What's Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!

October 20, 2022 | finance.yahoo.com

BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show

October 14, 2022 | markets.businessinsider.com

EQS-News: A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field

October 4, 2022 | proactiveinvestors.com

BioRestorative Therapies underway with Phase 2 clinical trial on stem cell-based BRTX-100

September 28, 2022 | finance.yahoo.com

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

September 27, 2022 | finance.yahoo.com

BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference

September 21, 2022 | forbes.com

Best Online Therapy Of 2022

September 7, 2022 | nz.finance.yahoo.com

BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14

September 7, 2022 | finance.yahoo.com

BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14

September 1, 2022 | finance.yahoo.com

Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst

August 31, 2022 | benzinga.com

Major Catalyst Near Term

August 25, 2022 | finance.yahoo.com

Giving Metabolism A Boost? BioRestorative Uses Science Surrounding Brown Fat Cells To Provide A Possible Breakthrough In Metabolic Disorders

August 16, 2022 | finance.yahoo.com

BioRestorative Therapies, Inc. (BRTX)

June 30, 2022 | seekingalpha.com

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

June 30, 2022 | finance.yahoo.com

BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

June 22, 2022 | finance.yahoo.com

EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BRTX Company Calendar

Today: 12/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Miscellaneous health & allied services, not elsewhere classified
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:BRTX
CUSIP: N/A
CIK: 1505497
Web: www.biorestorative.com
Phone: (631) 760-8100
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,300,000.00
Net Margins: -28,538.84%
Pretax Margin: -28,553.72%
Return on Equity: -178.73%
Return on Assets: -171.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.55
Quick Ratio: 23.55

Sales & Book Value

Annual Sales: $50,000.00
Price / Sales: 220.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.18 per share
Price / Book: 0.49

Miscellaneous

Outstanding Shares: 3,648,000
Free Float: 3,006,000
Market Cap: $11.02 million
Optionable: Not Optionable
Beta: 63.89

Key Executives

Mr. Lance Alstodt (Age 51)
Chairman, Pres & CEO
Comp: $275k

Mr. Francisco J. Silva (Age 47)
Chief Scientist, VP of R&D, Sec. and Director
Comp: $259.38k

Mr. Robert Eugene Kristal (Age 54)
Chief Financial Officer

Mr. Robert Paccasassi (Age 53)
VP of Quality Assurance & Regulatory Compliance

Dr. Wayne J. Olan M.D.
Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BRTX Stock - Frequently Asked Questions

Should I buy or sell BioRestorative Therapies stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BRTX shares.
View BRTX analyst ratings or view top-rated stocks.
How have BRTX shares performed in 2022?: BioRestorative Therapies' stock was trading at $4.34 at the start of the year. Since then, BRTX shares have decreased by 32.5% and is now trading at $2.93.
View the best growth stocks for 2022 here.
When did BioRestorative Therapies' stock split?: BioRestorative Therapies's stock reverse split on the morning of Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.
What other stocks do shareholders of BioRestorative Therapies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), PharmaCyte Biotech (PMCB), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX) and OPKO Health (OPK).

What is BioRestorative Therapies' stock symbol?: BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."
How do I buy shares of BioRestorative Therapies?: Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BioRestorative Therapies' stock price today?: One share of BRTX stock can currently be purchased for approximately $2.93.
How much money does BioRestorative Therapies make?: BioRestorative Therapies (OTCMKTS:BRTX) has a market capitalization of $10.69 million and generates $50,000.00 in revenue each year.
How can I contact BioRestorative Therapies?: BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The official website for the company is www.biorestorative.com. The company can be reached via phone at (631) 760-8100 or via email at ir@biorestorative.com.

This page (OTCMKTS:BRTX) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial